Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo Nordisk (NYSE:NVO) revealed 10 unusual trades.
Delving into the details, we found 70% of traders were bullish, while 10% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $112,088, and 8 were calls, valued at $304,824.
Expected Price Movements
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $120.0 and $175.0 for Novo Nordisk, spanning the last three months.
Volume & Open Interest Development
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Novo Nordisk's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Novo Nordisk's significant trades, within a strike price range of $120.0 to $175.0, over the past month.
Novo Nordisk Option Volume And Open Interest Over Last 30 Days
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NVO | PUT | SWEEP | BULLISH | 03/21/25 | $8.75 | $8.6 | $8.6 | $120.00 | $86.0K | 1.9K | 109 |
| NVO | CALL | TRADE | BULLISH | 03/21/25 | $8.75 | $8.55 | $8.7 | $135.00 | $52.2K | 750 | 10 |
| NVO | CALL | SWEEP | BULLISH | 12/20/24 | $9.1 | $9.0 | $9.1 | $125.00 | $45.5K | 309 | 51 |
| NVO | CALL | SWEEP | NEUTRAL | 03/21/25 | $1.25 | $1.22 | $1.25 | $175.00 | $45.1K | 292 | 363 |
| NVO | CALL | SWEEP | BULLISH | 11/15/24 | $4.7 | $4.55 | $4.65 | $130.00 | $37.2K | 619 | 166 |
About Novo Nordisk
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
After a thorough review of the options trading surrounding Novo Nordisk, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Present Market Standing of Novo Nordisk
- Trading volume stands at 1,564,079, with NVO's price down by -3.33%, positioned at $123.26.
- RSI indicators show the stock to be may be approaching oversold.
- Earnings announcement expected in 44 days.
What Analysts Are Saying About Novo Nordisk
In the last month, 3 experts released ratings on this stock with an average target price of $160.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access.* An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $160. * Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $160.* Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $160.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Novo Nordisk options trades with real-time alerts from Benzinga Pro.
